Invest in cancer diagnostics individualizing treatment

INVEST

Back the RNA AI layer of precision medicine.
Sequencing-based diagnostics is now standard oncology care — and the
most important information layer is still missing. OneRNA® supplies it.

Name

Email

By continuing, you agree to our Terms & Conditions and Privacy Policy.

Comment
Market Momentum

+60%
Sector market value growth for sequencing-in-cancer vs +15% S&P 500 · +35% XBI
$100B+
Equity segment with 2025 M&A activity hitting an all-time high, e.g., $20B aquisition of Exact Sciences by Abbott
$1.5B
Q1 revenue 4 oncology DNA-seq leaders · +44% YoY - outperforming other sectors
Patient stories

Patient Case 1
Metastatic thyroid cancer
OneRNA® identified RET overexpression. The patient enrolled in a Phase II trial of a RET-targeted therapy — now FDA-approved as Retevmo (selpercatinib) — responded, and has remained in remission for 5+ years.
Patient Case 2
Folicular Lymphoma
After rapid recurrence on two standard treatments and no response to two clinical trials, OneRNA® identified two FDA-approved drugs never before combined. On this novel combination, the patient responded and has remained in remission for 2+ years.
Traction

1
Grants
Raised $6.5M, 2026 pipeline of $50M (only 5-20% get funded)
2
Hospital
Established relationships and pipeline
3
Payor Code
RNA-seq specific payor code. In network with Medicare and some private payors
4
CLIA Validated
FDA not required
How do we compare
DNA sequencing has demonstrated its clinical value, but missing a very important layer of information. Both types of testing are necessary to uncover all options for a patient and can be billed under separate payor codes
DNA Panels
500-geneTypical 500 genes -> binary test
OneRNA
20,000 RNA's -> quantitatively
40% of patients matched to one drug
Drops to 26% in low mutation tumors
Almost 100% of patients matched to a drug
Matching to typically more than one option
Does not detect
Over-Expression
Fusions
Immune therapy targets
Tumor Microenvironment
Detects
Over-expression
Fusions
Immune therapy targets
Tumor Microenvironment
Subscribe

* indicates required

Email Address *
First Name *
Last Name *
Phone
Who I am *
Company name
Comment

Call Us

Contact

Home

Store

Back the RNA AI layer of precision medicine.

Sequencing-based diagnostics is now standard oncology care — and the

most important information layer is still missing. OneRNA® supplies it.

Market Momentum

+60%

$100B+

$1.5B

Patient stories

Patient Case 1

OneRNA® identified RET overexpression. The patient enrolled in a Phase II trial of a RET-targeted therapy — now FDA-approved as Retevmo (selpercatinib) — responded, and has remained in remission for 5+ years.

Patient Case 2

After rapid recurrence on two standard treatments and no response to two clinical trials, OneRNA® identified two FDA-approved drugs never before combined. On this novel combination, the patient responded and has remained in remission for 2+ years.

Traction

Grants

Hospital

Payor Code

CLIA Validated

How do we compare

DNA sequencing has demonstrated its clinical value, but missing a very important layer of information. Both types of testing are necessary to uncover all options for a patient and can be billed under separate payor codes

DNA Panels

500-geneTypical 500 genes -> binary test

OneRNA

20,000 RNA's -> quantitatively

40% of patients matched to one drug

Drops to 26% in low mutation tumors

Almost 100% of patients matched to a drug

Matching to typically more than one option

Does not detect

Detects

Subscribe